Halozyme Therapeutics, Inc. (HALO)

In the past six months, Halozyme's stock has experienced several notable events. The company reported its Q4 2025 earnings on February 17, 2026, where it posted a loss of -$0.35 earnings per share (EPS), significantly missing the consensus estimate of $2.07 profit. In December 2025, Halozyme completed the acquisition of Surf Bio, Inc., expanding its drug delivery technology portfolio. Also in December 2025, a German court granted Halozyme's request for a preliminary injunction against Merck Sharp & Dohme Corp. In March 2026, Halozyme appointed David Ramsay as Interim Chief Financial Officer. Analysts have provided varied price targets and ratings for HALO stock during this period. The stock's 52-week range has been between $47.50 and $82.22.

Based on the available information, there is no explicit mention or indication of significant demand seasonality for Halozyme Therapeutics, Inc.'s products and services. The company's revenue growth is primarily driven by royalty revenue from its ENHANZE® platform and product sales, which are tied to the uptake of partnered pharmaceutical products and its proprietary offerings.

Halozyme Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing innovative drug delivery technologies and oncology therapies. The company's core business revolves around its proprietary ENHANZE® drug delivery technology, which utilizes the recombinant human hyaluronidase enzyme (rHuPH20) to facilitate the subcutaneous (SC) delivery of injected drugs and fluids. Halozyme develops, manufactures, and commercializes drug-device combination products, including advanced auto-injector technologies. The company also licenses its ENHANZE® technology to leading pharmaceutical companies for use with their therapies. Halozyme's development pipeline has historically focused on clinical and pre-clinical stage oncology products, though it halted development of PEGPH20 in November 2019.

Halozyme Therapeutics, Inc. is headquartered in San Diego, California, United States, and serves a worldwide market. Its products are sold in the United States, Switzerland, Belgium, and Japan. The company has acknowledged that its geographic concentration in the U.S. may limit its ability to tap into emerging markets and exposes it to the volatility of the U.S. healthcare regulatory environment.

In the past year, Halozyme's brand reputation, particularly among investors, appears to have been impacted by recent financial performance and deal economics. The Q4 2025 earnings miss raised questions among investors about the company's profitability and the sustainability of its growth trajectory. Some market sentiment suggests that the market is "not impressed with the economics of the recent deals" and desires reassurance regarding the replacement of future revenues/royalties. There are also observations that the market "literally HATES this company," despite it being considered a "great company" by some.

Halozyme Therapeutics, Inc. has a strong presence of institutional investors, which are the dominant force in its ownership structure. As of May 2026, the company has 642 institutional owners holding a total of 121,648,649 shares. Institutional ownership accounts for approximately 88.84% of the company, with individuals holding about 1.02%. The largest individual shareholder is Randal J. Kirk, owning 26.63 million shares, representing 22.57% of the company.